Professionals 444 results
Capabilities 75 results
Practice Area
Product Liability & Mass Torts
Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of
extensive trial experience and expansive technical knowledge.
Practice Area
Derivatives & Structured Products
derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement
issues related to commodities and derivatives.
Industry
fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility,
drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable ...Read more
Experience 125 results
Experience
|January 16, 2025
Winston Wins Dismissal of False Advertising Claims Against Birdseed Manufacturer
Experience
|January 4, 2025
Experience
|December 23, 2024
Winston advises Atlantic Sustainable Catch in its acquisition of Atlantic Capes Fisheries
Insights & News 2,059 results
Client Alert
|April 4, 2025
|1 Min Read
Implications of Tariffs on the Energy and Infrastructure Industry
Annual United States Goods Trade Deficits” Executive Order (the EO), thereby imposing sweeping tariffs on imports to the United States. The EO places, with
some exemptions, a baseline 10% reciprocal tariff on all imports, effective April 5, as well as additional country-specific tariff rates for nearly 60 ...Read more
Product Liability & Mass Torts Digest
|April 3, 2025
|5 Min Read
Supreme Court Has a Chance to (Re-)Clarify Albrecht Impossibility Preemption Test
A cert petition filed in March in the long-running In re Fosamax (Alendronate Sodium) Products Liability Litigation gives the Supreme Court a chance to clarify—for the second time—the Third Circuit’s restrictive application of the impossibility preemption defense.
Class Action Insider
|April 3, 2025
|3 Min Read
The Supreme Court to Soon Resolve Divide over Certification Where Some Class Members Lack Standing
On January 24, 2025, the United States Supreme Court ordered expedited briefing to resolve the current circuit split over whether a federal court may certify a class action pursuant to Federal Rule of Civil Procedure 23(b)(3) when some members of the proposed class lack any Article III injury.
Other Results 85 results
Law Glossary
What Are Interchangeable Biological Products?
in any given patient. A biosimilar product that is deemed to be interchangeable by the FDA means the biosimilar product can be substituted for the reference
product by a pharmacist without consulting the prescriber. The specific requirements for substitution vary by state.
Site Content
cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires
scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, ma...Read more
Site Content
clinically meaningful differences compared to a reference product in terms of safety, purity, and potency as demonstrated through human pharmacokinetic
and pharmacodynamics studies. Because of their complexity, biosimilars are unlikely to be identical replicates of their comparable reference products.